Ubican brings well-known brands and is a trusted vendor with an established sales and marketing program.
VANCOUVER, BC / December 7, 2020 / Chemesis International Inc. (CSE:CSI.U) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces an initial placement of its VICKI self-checkout solution at Reebok LAB in West Hollywood, California. The placement will allow the team to develop a sales strategy and validate the demand for CBD products in fitness centres and gyms across the United States.
This milestone gives Chemesis’ the ability to build on an approach specific to the fitness industry and the sports nutrition market, which is valued at over 15.6 billion USD. The Company sees an incredible opportunity in the fitness space across the United States and will continue to work to further expand its placements at gyms and fitness centres. The Company has been working with the Reebok LAB team to develop an education platform as well as products that may enhance athlete’s performance. Chemesis anticipates the VICKI will be placed in the coming weeks.
The Reebok LAB is a widely recognized gym in the fitness community, the gym is sponsored by Reebok and is led by elite trainers that have trained both professional athletes and actors. The gym is a CrossFit gym that is focused on whole body strength and conditioning, mobility, and gymnastics.
“The placement in a prominent gym in West Hollywood gives Chemesis incredible exposure into the fitness industry,” said President of Chemesis, Josh Rosenberg. “Reebok Lab is led by a world-renowned team of fitness experts and trainers, including owner, Yumi Lee, who has trained Hollywood’s elite and professional athletes. The team is confident that with their support this will be the beginning of many additional placements of VICKI’s across the United States in gyms and fitness centres.”
1 (604) 398-3378
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the ability of the Company to continue to operate under the Licenses, and the ability of the Company to engage in any administrative process with the Department of Health. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements including, among other things, the risks that the Company will not be able to maintain or continue licensed activities under the Licences as currently being conducted, or at all, and that the Company’s products and plans will vary significantly as a result, and that the Company will not be permitted to engage with the Department of Health through an administrative or other process to address the concerns raised. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release